🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 12 Florida 11 Arizona 9 Colorado 7 District of Columbia 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals4 Hoffmann-La Roche3 TG Therapeutics, Inc.3 Zenas BioPharma (USA), LLC1 Sanofi1
State
California12 Florida11 Arizona9 Colorado7 District of Columbia7
All 23 states
Target enrolment
to
12 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514Relapsing Multiple Sclerosis
TG Therapeutics, Inc.
Observational
16
California, Georgia, Massachusetts, North Carolina, Tennessee
2024-03-26
Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963Relapsing Multiple Sclerosis
TG Therapeutics, Inc.
Phase 3
800
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-06-13
Active, closed
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
NCT05119569Relapsing Multiple Sclerosis
Hoffmann-La Roche
Phase 2
109
California, Nevada
2022-03-01
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Illinois
2021-12-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas
2021-12-13
Active, closed
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023Relapsing Multiple Sclerosis
Hoffmann-La Roche
Phase 3
751
Alabama, Arizona, California, District of Columbia, Florida, Indiana, Kansas, Massachusetts
2021-03-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
Hoffmann-La Roche
Phase 3
746
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Louisiana
2021-03-17
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii
2018-12-28
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.